Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.

European urology oncology - 1 Aug 2026

Compérat Eva M, Hartmann Arndt, Allory Yves, Bellosillo Beatriz, Caetano Moreira Oliveira Rui Pedro, Chiappetta Caterina, Hodeib Farah, Hubank Michael, Klümper Niklas, Loriot Yohann, Penault-Llorca Frédérique, Rijken Astrid, Speel Ernst-Jan M, Szabados Bernadett, Bempt Isabelle Vanden, Van Leenders Geert J L H, Vescovo Mariavittoria, Eckstein Markus

Abstract excerpt

CONTEXT: Metastatic urothelial cancer (mUC) is associated with diverse genomic alterations, including frequent FGFR3 mutations that influence survival outcomes and treatment responses. Erdafitinib, a targeted therapy, has shown improved survival in patients with locally advanced (LA) or mUC harbouring FGFR3 alterations, reinforcing the importance of timely FGFR3 testing. OBJECTIVE: This article aims to provide...

Read the complete abstract on PubMed

Topics

Humans
Receptor, Fibroblast Growth Factor, Type 3
Carcinoma, Transitional Cell
Urologic Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Urinary Bladder Neoplasms

Practice Guidelines as Topic

Source

Identifiers

PMID: 42448514
DOI: 10.1016/j.euo.2026.06.003

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.PMID 42448514Read ↗

Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives.Semantic proximity Read ↗

Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing.Semantic proximity Read ↗

Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinomaSemantic proximity Read ↗

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.Semantic proximity Read ↗

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: A dual-institutional experience.Semantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.Semantic proximity Read ↗

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer.Semantic proximity Read ↗

[Molecular diagnostics of bladder cancer-practical ramifications].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.